FENC logo

FENNEC PHARMACEUTICALS INC

FENCNASDAQ
πŸ† #2815 by market capEarnings Mar 22 Β· PostUS Equity
$13.09β–Ό $0.36 (βˆ’2.68%)
Market closed Β· at close
πŸ””
Track FENC
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.7%
7dβ–² 12.4%
14dβ–² 33.7%
30dβ–² 30.0%
ytdβ–² 70.0%
1yβ–² 66.9%
🏦Market Cap
$462M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-6.1%
Declining
πŸ“ŠGross Margin
94.1%
High
πŸ’΅FCF Margin
4.7%
Moderate
βš–οΈP/S Ratio
7.0x
Fair
Otter Score
56
Fair

Trading Snapshot

Day Range
$12.64 – $13.25
52-Week Range
$5.65 – $13.85
Volume (shares)
398,269
Avg Volume (shares)
β€”
Shares Outstanding
35.3M
Next Earnings
2027-03-22

Fundamentals Snapshot

Annual Revenue
$45M
Last Q Revenue
$18M
P/E Ratio
571.6
P/S Ratio
7.0x
EPS (TTM)
$0.06
Dividend Yield
0.00%
Dilution (1yr)
+13.5%
FENC logo

FENNEC PHARMACEUTICALS INC

FENC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$45Mβ–Ό βˆ’6.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
91.6%β–Ό βˆ’1.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$6Mβ–Ό βˆ’356.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$12Mβ–Ό βˆ’146.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
31.2Mβ–² +13.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$37Mβ–² +$29M YoY
StockOtter Β· stockotter.space

About FENNEC PHARMACEUTICALS INC

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
56/100

Analyst Ratings

β“˜
Consensus
Buy
12 analysts
Strong Buy3
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

Zacks Investment ResearchΒ·5d ago

Adherex Technologies (FENC) is on the Move, Here's Why the Trend Could be Sustainable

Adherex Technologies (FENC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-t

Zacks Investment ResearchΒ·9d ago

What Makes Adherex Technologies (FENC) a New Strong Buy Stock

Adherex Technologies (FENC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment ResearchΒ·9d ago

How Much Upside is Left in Adherex Technologies (FENC)? Wall Street Analysts Think 57.8%

The consensus price target hints at a 57.8% upside potential for Adherex Technologies (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisio

Seeking AlphaΒ·10d ago

Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript

MarketBeatΒ·10d ago

Adherex Technologies Q3 Earnings Call Highlights

Fennec Pharmaceuticals NASDAQ: FENC reported third-quarter net product sales of $19.4 million, up 56% from a year earlier, as use of its hearing-protection drug PEDMARK expanded among new and existing customers.

Zacks Investment ResearchΒ·10d ago

Adherex Technologies Inc. (FENC) Q3 Earnings and Revenues Beat Estimates

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.02 per share a year ago.